ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in ...
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer ...
Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to ...
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, ...
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results